Journal of Diabetes & Metabolism

Journal of Diabetes & Metabolism
Open Access

ISSN: 2155-6156

+44 1477412632


Imeglimin: Therapeutic Option for Achieving Glycemic Control

Dr. Subhash Kumar*

Imeglimin is a new class of drug which has introduced recently. The molecular mechanisms are unknown, although imeglimin improves insulin sensitivity in humans. Pre-clinical studies had confirmed that imeglimin favouring lipid oxidation in liver and preserving mitochondrial function from oxidative stress, therefore normalizes glucose tolerance and insulin sensitivity. The main objective of this review article is to highlight updates of new class of drug which is imeglimin and generated a huge interest after recently conducted EASD at Barcelona.

Published Date: 2019-12-04; Received Date: 2019-10-11